Research report from CRISIL: -
CRISIL-Research_Market-final-report_with-addendum-July-Nov-2021_30112021.pdf (2.5 MB)
Sections 4 & 6 has relevant information (presumably accurate) showing growth prospects
across the different therapeutic areas and the molecules under each. Supriya
currently operates in almost all given therapeutic areas.
Based on the above, an apple to apple comparison (more close) for Supriya would be Divis, Teva and possibly Wanbury.
One thing I found strange though is Supriya seems highlighted at multiple places in the report as if this report was prepared by CRISIL to promote Supriya. Moreover, ICRA had moved its rating to “Issuer not co-operating” category in May 2021 and subsequently took it down in June 2021.
Subscribe To Our Free Newsletter |